Special Report
Bone Marrow Transplantation (2008) 41, 687–705; doi:10.1038/sj.bmt.1705956; published online 17 December 2007
The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products
A Gratwohl1, H Baldomero1, K Frauendorfer2, V Rocha3, J Apperley4 and D Niederwieser5 for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE)
- 1Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland
- 2Institute for Operations Research and Computational Finance, University of St Gallen, St Gallen, Switzerland
- 3Eurocord, Department of Haematology, Hôpital St Louis, Paris, France
- 4Department of Haematology, Hammersmith Hospital, London, UK
- 5Division of Hematology/Oncology, Department of Internal Medicine, University Hospital, Leipzig, Germany
Correspondence: Professor Dr A Gratwohl, Hematology, University Hospital Basel, Basel CH-4031, Switzerland. E-mail: hematology@uhbs.ch
Received 25 September 2007; Revised 12 November 2007; Accepted 13 November 2007; Published online 17 December 2007.
Abstract
This report describes the hematopoietic stem cell transplantation (HSCT) activity in Europe in 2006 by indication, donor type and stem cell source. It illustrates differences compared to previous years and concentrates on the use of cord blood transplants. In 2006, there were 25 050 first HSCT, 9661 allogeneic (39% ), 15 389 autologous (61% ) and 3690 additional re- or multiple transplants reported from 605 centers in 43 participating countries. Main indications were leukemias (7963 (32% ; 85% allogeneic)); lymphomas (14 169 (56% ; 89% autologous)); solid tumors (1564 (6% ; 95% autologous)); non-malignant disorders (1242 (5% ; 90% allogeneic)) and non-classified 'others' (112 (1% )). There was an increase in allogeneic HSCT of 9% when compared to 2005, while autologous HSCT numbers remained similar. There were 544 allogeneic cord blood HSCT, which corresponds to 5% of all allogeneic HSCT. The majority, 67% , were used for patients with leukemia. The highest percentage of cord blood transplants, 27% , was seen for inherited disorders of metabolism. No autologous cord blood transplants were reported. The highest increase in allogeneic HSCT was observed for AML, which comprises 31% of all allogeneic HSCT. Numbers of autologous HSCT remained similar in most main indications. This data provide an update of the current HSCT experience in Europe.
Keywords:
hematopoietic stem cell transplantation, Europe, transplant rates, cord blood transplants, unrelated transplants
